Evidence map›Paper›PMID 40048128›Full record

ArticleCardiovascular toxicology2025

Apatinib-Induced Hypertension Correlates with Improved Prognosis in Solid Tumor Patients.

Caie Li, Jie Ma, Qiongying Wang, Liping Ma, Juncheng Han, Yali Qi, Xiaxia Pei, Jing Yu

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Cardiovascular toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Caie LiCenter of Hypertension, Department of Cardiology, The Second Hospital of Lanzhou University, Lanzhou, 730030, China.
Jie MaCenter of Hypertension, Department of Cardiology, The Second Hospital of Lanzhou University, Lanzhou, 730030, China.
Qiongying WangCenter of Hypertension, Department of Cardiology, The Second Hospital of Lanzhou University, Lanzhou, 730030, China.
Liping MaDepartment of Cardiology, The First People's Hospital of Tianshui, Tianshui, 741000, China.
Juncheng HanCenter of Hypertension, Department of Cardiology, The Second Hospital of Lanzhou University, Lanzhou, 730030, China.
Yali QiDepartment of Oncology, The Second Hospital of Lanzhou University, Lanzhou, 730030, China.
Xiaxia PeiDepartment of Oncology, The Second Hospital of Lanzhou University, Lanzhou, 730030, China.
Jing YuCenter of Hypertension, Department of Cardiology, The Second Hospital of Lanzhou University, Lanzhou, 730030, China. ery_jyu@lzu.edu.cn.

Funding

Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital CY2024-MS-B11National Natural Science Foundation of China NSFC- 82460086Science and Technology Department of Gansu Province 23JRRA1506
6 · The paper itself

Abstract

This study evaluated the occurrence of apatinib-induced hypertension and its impact on the prognosis of patients with solid tumors. A retrospective cohort study with prospective follow-up was conducted on 769 patients treated with apatinib from 2014 to 2021 across three hospitals. Patients were categorized into hypertension and non-hypertension groups. The primary outcome was overall survival (OS), with progression-free survival (PFS) as a secondary outcome. Apatinib-induced hypertension occurred in 33.3% of patients and was associated with significantly longer OS (HR 0.40, 95% CI [0.37-0.48], p < 0.0001) and PFS (HR 0.41, 95% CI [0.35-0.49], p < 0.001). Subgroup analysis confirmed these findings in all cancer types, except for PFS in non-small cell lung cancer. Hypertension may serve as a predictive biomarker for improved anti-tumor efficacy.

Indexed as

Antineoplastic AgentsBlood PressureHypertensionNeoplasmsProtein Kinase InhibitorsPyridinesAdultAgedFemaleHumansMaleMiddle AgedProgression-Free SurvivalRetrospective StudiesRisk AssessmentRisk FactorsAntineoplastic AgentsapatinibProtein Kinase InhibitorsPyridinesApatinibCardio-oncologyCardiotoxicityHypertensionVEGF inhibitors

Identifiers

PMID40048128

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.